nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Gemcitabine—pancreatic cancer	0.285	0.515	CiPCiCtD
Nelarabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—pancreatic cancer	0.268	0.485	CiPCiCtD
Nelarabine—POLA1—Gemcitabine—pancreatic cancer	0.116	0.619	CbGbCtD
Nelarabine—DCK—Gemcitabine—pancreatic cancer	0.0717	0.381	CbGbCtD
Nelarabine—Cytarabine—Gemcitabine—pancreatic cancer	0.0628	0.35	CrCrCtD
Nelarabine—Azacitidine—Gemcitabine—pancreatic cancer	0.0596	0.333	CrCrCtD
Nelarabine—Decitabine—Gemcitabine—pancreatic cancer	0.0568	0.317	CrCrCtD
Nelarabine—DCK—Pyrimidine salvage reactions—TYMP—pancreatic cancer	0.00197	0.0971	CbGpPWpGaD
Nelarabine—DGUOK—Nucleotide metabolism—TYMP—pancreatic cancer	0.00114	0.0563	CbGpPWpGaD
Nelarabine—DGUOK—Nucleotide metabolism—DPYD—pancreatic cancer	0.000908	0.0447	CbGpPWpGaD
Nelarabine—DCK—Pyrimidine metabolism—TYMP—pancreatic cancer	0.0009	0.0443	CbGpPWpGaD
Nelarabine—DCK—Pyrimidine metabolism—DPYD—pancreatic cancer	0.000714	0.0351	CbGpPWpGaD
Nelarabine—DCK—Topotecan—Irinotecan—pancreatic cancer	0.000674	0.568	CbGdCrCtD
Nelarabine—DGUOK—Nucleotide metabolism—TYMS—pancreatic cancer	0.000517	0.0255	CbGpPWpGaD
Nelarabine—Fludarabine—SLC29A1—pancreatic cancer	0.000424	0.19	CrCbGaD
Nelarabine—Ribavirin—SLC29A1—pancreatic cancer	0.000422	0.188	CrCbGaD
Nelarabine—DCK—Pyrimidine metabolism—TYMS—pancreatic cancer	0.000407	0.02	CbGpPWpGaD
Nelarabine—POLA1—G1/S-Specific Transcription—TYMS—pancreatic cancer	0.000392	0.0193	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—TYMP—pancreatic cancer	0.00038	0.0187	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—SHH—pancreatic cancer	0.000369	0.0181	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—HEY2—pancreatic cancer	0.000352	0.0173	CbGpPWpGaD
Nelarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—RB1—pancreatic cancer	0.000351	0.0173	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—TYMP—pancreatic cancer	0.000351	0.0173	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—RBBP8—pancreatic cancer	0.000338	0.0167	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—GADD45A—pancreatic cancer	0.000313	0.0154	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—JAG1—pancreatic cancer	0.000313	0.0154	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—HSPA1B—pancreatic cancer	0.000309	0.138	CrCbGaD
Nelarabine—Adenosine triphosphate—ACVR1B—pancreatic cancer	0.000309	0.138	CrCbGaD
Nelarabine—ADA—p73 transcription factor network—WT1—pancreatic cancer	0.000303	0.0149	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—DPYD—pancreatic cancer	0.000301	0.0148	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—JAG2—pancreatic cancer	0.000289	0.0142	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—HSPA1A—pancreatic cancer	0.000282	0.126	CrCbGaD
Nelarabine—DCK—Nucleotide metabolism—DPYD—pancreatic cancer	0.000278	0.0137	CbGpPWpGaD
Nelarabine—Cytarabine—SLC29A1—pancreatic cancer	0.000273	0.122	CrCbGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—pancreatic cancer	0.000271	0.0133	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—HES1—pancreatic cancer	0.000256	0.0126	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—pancreatic cancer	0.000231	0.0114	CbGpPWpGaD
Nelarabine—POLA1—Extension of Telomeres—TERT—pancreatic cancer	0.000223	0.011	CbGpPWpGaD
Nelarabine—DCK—Clomifene—Tamoxifen—pancreatic cancer	0.000208	0.175	CbGdCrCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TFF1—pancreatic cancer	0.000197	0.00972	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—pancreatic cancer	0.000193	0.00951	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—BRCA2—pancreatic cancer	0.000179	0.00879	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—TYMS—pancreatic cancer	0.000172	0.00845	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—HES1—pancreatic cancer	0.000161	0.00792	CbGpPWpGaD
Nelarabine—DCK—Doxorubicin—Epirubicin—pancreatic cancer	0.000158	0.134	CbGdCrCtD
Nelarabine—DCK—Nucleotide metabolism—TYMS—pancreatic cancer	0.000158	0.0078	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—RB1—pancreatic cancer	0.000156	0.0077	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—pancreatic cancer	0.000153	0.00755	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—AHR—pancreatic cancer	0.000147	0.00725	CbGpPWpGaD
Nelarabine—DCK—Epirubicin—Doxorubicin—pancreatic cancer	0.000147	0.124	CbGdCrCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—pancreatic cancer	0.000145	0.00715	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—DAXX—pancreatic cancer	0.000143	0.00706	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—pancreatic cancer	0.000137	0.00676	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PRSS1—pancreatic cancer	0.000137	0.00675	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—SYCP1—pancreatic cancer	0.000133	0.00653	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—TYMS—pancreatic cancer	0.000122	0.00602	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ARG2—pancreatic cancer	0.000119	0.00585	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—RB1—pancreatic cancer	0.000115	0.00567	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—EZH2—pancreatic cancer	0.000111	0.00547	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—AKT1—pancreatic cancer	0.000111	0.0494	CrCbGaD
Nelarabine—Adenosine monophosphate—SRC—pancreatic cancer	0.000109	0.0487	CrCbGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—pancreatic cancer	0.000106	0.00523	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TYMP—pancreatic cancer	0.000104	0.00512	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000101	0.00497	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—TERT—pancreatic cancer	0.000101	0.00497	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—PLAU—pancreatic cancer	0.000101	0.00497	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RB1—pancreatic cancer	9.84e-05	0.00485	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN2A—pancreatic cancer	9.64e-05	0.00475	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	9.06e-05	0.00446	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—pancreatic cancer	9.02e-05	0.00444	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	8.95e-05	0.00441	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—TYMS—pancreatic cancer	8.87e-05	0.00437	CbGpPWpGaD
Nelarabine—POLA1—Chromosome Maintenance—TERT—pancreatic cancer	8.42e-05	0.00414	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GLP1R—pancreatic cancer	8.38e-05	0.00413	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—RB1—pancreatic cancer	8.29e-05	0.00408	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—DPYD—pancreatic cancer	8.24e-05	0.00406	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—pancreatic cancer	8.15e-05	0.00401	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TYMS—pancreatic cancer	8.05e-05	0.00396	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PPP2R5B—pancreatic cancer	7.89e-05	0.00389	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC2A2—pancreatic cancer	7.82e-05	0.00385	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	7.82e-05	0.00385	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	7.69e-05	0.00379	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—TYMS—pancreatic cancer	7.48e-05	0.00368	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	7.31e-05	0.0036	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN2A—pancreatic cancer	7.29e-05	0.00359	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—pancreatic cancer	7.2e-05	0.00355	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—NRAS—pancreatic cancer	7.02e-05	0.00345	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—MYC—pancreatic cancer	6.86e-05	0.00338	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RBBP8—pancreatic cancer	6.79e-05	0.00334	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—RB1—pancreatic cancer	6.66e-05	0.00328	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	6.59e-05	0.00324	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—MYC—pancreatic cancer	6.53e-05	0.00322	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—RB1—pancreatic cancer	6.25e-05	0.00307	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CD44—pancreatic cancer	6.06e-05	0.00298	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—pancreatic cancer	6.04e-05	0.00297	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—RB1—pancreatic cancer	6.02e-05	0.00296	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	5.96e-05	0.00293	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PPP2R5B—pancreatic cancer	5.9e-05	0.00291	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	5.86e-05	0.00289	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GCG—pancreatic cancer	5.81e-05	0.00286	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	5.77e-05	0.00284	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—PPARG—pancreatic cancer	5.7e-05	0.00281	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	5.66e-05	0.00279	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—STK11—pancreatic cancer	5.46e-05	0.00269	CbGpPWpGaD
Nelarabine—POLA1—S Phase—RB1—pancreatic cancer	5.46e-05	0.00269	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	5.35e-05	0.00263	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PPP2R5B—pancreatic cancer	5.28e-05	0.0026	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—FOXM1—pancreatic cancer	5.26e-05	0.00259	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—pancreatic cancer	5.13e-05	0.00253	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—RB1—pancreatic cancer	5.07e-05	0.0025	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—MYC—pancreatic cancer	4.94e-05	0.00243	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	4.82e-05	0.00237	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—FOXM1—pancreatic cancer	4.7e-05	0.00232	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TYMS—pancreatic cancer	4.7e-05	0.00231	CbGpPWpGaD
Nelarabine—Anorexia—Gemcitabine—pancreatic cancer	4.6e-05	0.000813	CcSEcCtD
Nelarabine—Dizziness—Erlotinib—pancreatic cancer	4.59e-05	0.000812	CcSEcCtD
Nelarabine—ADA—Metabolism—PRSS1—pancreatic cancer	4.55e-05	0.00224	CbGpPWpGaD
Nelarabine—Anorexia—Fluorouracil—pancreatic cancer	4.52e-05	0.000799	CcSEcCtD
Nelarabine—Hypotension—Gemcitabine—pancreatic cancer	4.51e-05	0.000797	CcSEcCtD
Nelarabine—Eye disorder—Docetaxel—pancreatic cancer	4.51e-05	0.000796	CcSEcCtD
Nelarabine—Insomnia—Irinotecan—pancreatic cancer	4.48e-05	0.000792	CcSEcCtD
Nelarabine—Cardiac disorder—Docetaxel—pancreatic cancer	4.47e-05	0.000791	CcSEcCtD
Nelarabine—Vomiting—Tamoxifen—pancreatic cancer	4.47e-05	0.000789	CcSEcCtD
Nelarabine—Hypoglycaemia—Doxorubicin—pancreatic cancer	4.46e-05	0.000788	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	4.46e-05	0.00219	CbGpPWpGaD
Nelarabine—Paraesthesia—Irinotecan—pancreatic cancer	4.45e-05	0.000786	CcSEcCtD
Nelarabine—Lethargy—Doxorubicin—pancreatic cancer	4.44e-05	0.000784	CcSEcCtD
Nelarabine—Hypotension—Fluorouracil—pancreatic cancer	4.43e-05	0.000784	CcSEcCtD
Nelarabine—Ataxia—Epirubicin—pancreatic cancer	4.42e-05	0.000781	CcSEcCtD
Nelarabine—Vomiting—Erlotinib—pancreatic cancer	4.42e-05	0.000781	CcSEcCtD
Nelarabine—Dyspnoea—Irinotecan—pancreatic cancer	4.42e-05	0.000781	CcSEcCtD
Nelarabine—Somnolence—Irinotecan—pancreatic cancer	4.4e-05	0.000778	CcSEcCtD
Nelarabine—Blood creatinine increased—Epirubicin—pancreatic cancer	4.4e-05	0.000778	CcSEcCtD
Nelarabine—Headache—Tamoxifen—pancreatic cancer	4.4e-05	0.000778	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	4.4e-05	0.000777	CcSEcCtD
Nelarabine—Angiopathy—Docetaxel—pancreatic cancer	4.37e-05	0.000773	CcSEcCtD
Nelarabine—Dehydration—Epirubicin—pancreatic cancer	4.37e-05	0.000773	CcSEcCtD
Nelarabine—Insomnia—Gemcitabine—pancreatic cancer	4.37e-05	0.000771	CcSEcCtD
Nelarabine—Headache—Erlotinib—pancreatic cancer	4.35e-05	0.000769	CcSEcCtD
Nelarabine—Osteoarthritis—Doxorubicin—pancreatic cancer	4.35e-05	0.000769	CcSEcCtD
Nelarabine—Pain in extremity—Doxorubicin—pancreatic cancer	4.35e-05	0.000769	CcSEcCtD
Nelarabine—Mediastinal disorder—Docetaxel—pancreatic cancer	4.35e-05	0.000768	CcSEcCtD
Nelarabine—Paraesthesia—Gemcitabine—pancreatic cancer	4.33e-05	0.000766	CcSEcCtD
Nelarabine—Chills—Docetaxel—pancreatic cancer	4.33e-05	0.000764	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	4.32e-05	0.000764	CcSEcCtD
Nelarabine—Asthenia—Sunitinib—pancreatic cancer	4.32e-05	0.000763	CcSEcCtD
Nelarabine—Decreased appetite—Irinotecan—pancreatic cancer	4.31e-05	0.000761	CcSEcCtD
Nelarabine—Dyspnoea—Gemcitabine—pancreatic cancer	4.3e-05	0.00076	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	4.29e-05	0.00211	CbGpPWpGaD
Nelarabine—Insomnia—Fluorouracil—pancreatic cancer	4.29e-05	0.000759	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	4.29e-05	0.00211	CbGpPWpGaD
Nelarabine—Somnolence—Gemcitabine—pancreatic cancer	4.29e-05	0.000758	CcSEcCtD
Nelarabine—Hypokalaemia—Epirubicin—pancreatic cancer	4.28e-05	0.000756	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	4.28e-05	0.000756	CcSEcCtD
Nelarabine—Fatigue—Irinotecan—pancreatic cancer	4.27e-05	0.000755	CcSEcCtD
Nelarabine—Paraesthesia—Fluorouracil—pancreatic cancer	4.26e-05	0.000753	CcSEcCtD
Nelarabine—Pain—Irinotecan—pancreatic cancer	4.24e-05	0.000749	CcSEcCtD
Nelarabine—Constipation—Irinotecan—pancreatic cancer	4.24e-05	0.000749	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	4.23e-05	0.000748	CcSEcCtD
Nelarabine—Dyspnoea—Fluorouracil—pancreatic cancer	4.23e-05	0.000748	CcSEcCtD
Nelarabine—Mental disorder—Docetaxel—pancreatic cancer	4.22e-05	0.000746	CcSEcCtD
Nelarabine—Somnolence—Fluorouracil—pancreatic cancer	4.22e-05	0.000746	CcSEcCtD
Nelarabine—DCK—Metabolism—PRSS1—pancreatic cancer	4.2e-05	0.00207	CbGpPWpGaD
Nelarabine—Malnutrition—Docetaxel—pancreatic cancer	4.2e-05	0.000742	CcSEcCtD
Nelarabine—Decreased appetite—Gemcitabine—pancreatic cancer	4.2e-05	0.000741	CcSEcCtD
Nelarabine—Nausea—Tamoxifen—pancreatic cancer	4.17e-05	0.000737	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	4.17e-05	0.000736	CcSEcCtD
Nelarabine—Fatigue—Gemcitabine—pancreatic cancer	4.16e-05	0.000735	CcSEcCtD
Nelarabine—Muscular weakness—Epirubicin—pancreatic cancer	4.15e-05	0.000733	CcSEcCtD
Nelarabine—Constipation—Gemcitabine—pancreatic cancer	4.13e-05	0.000729	CcSEcCtD
Nelarabine—Pain—Gemcitabine—pancreatic cancer	4.13e-05	0.000729	CcSEcCtD
Nelarabine—Nausea—Erlotinib—pancreatic cancer	4.13e-05	0.000729	CcSEcCtD
Nelarabine—Decreased appetite—Fluorouracil—pancreatic cancer	4.13e-05	0.000729	CcSEcCtD
Nelarabine—Diarrhoea—Sunitinib—pancreatic cancer	4.12e-05	0.000727	CcSEcCtD
Nelarabine—Dysgeusia—Docetaxel—pancreatic cancer	4.11e-05	0.000726	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	4.11e-05	0.00202	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	4.1e-05	0.000724	CcSEcCtD
Nelarabine—Abdominal distension—Epirubicin—pancreatic cancer	4.09e-05	0.000723	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—pancreatic cancer	4.09e-05	0.000723	CcSEcCtD
Nelarabine—Feeling abnormal—Irinotecan—pancreatic cancer	4.08e-05	0.000722	CcSEcCtD
Nelarabine—Blood creatinine increased—Doxorubicin—pancreatic cancer	4.07e-05	0.00072	CcSEcCtD
Nelarabine—Back pain—Docetaxel—pancreatic cancer	4.06e-05	0.000717	CcSEcCtD
Nelarabine—Pain—Fluorouracil—pancreatic cancer	4.06e-05	0.000717	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—pancreatic cancer	4.06e-05	0.002	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Irinotecan—pancreatic cancer	4.05e-05	0.000716	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—pancreatic cancer	4.04e-05	0.000715	CcSEcCtD
Nelarabine—Dizziness—Sunitinib—pancreatic cancer	3.98e-05	0.000703	CcSEcCtD
Nelarabine—Feeling abnormal—Gemcitabine—pancreatic cancer	3.98e-05	0.000703	CcSEcCtD
Nelarabine—Hypokalaemia—Doxorubicin—pancreatic cancer	3.96e-05	0.000699	CcSEcCtD
Nelarabine—ADA—Metabolism—ARG2—pancreatic cancer	3.95e-05	0.00194	CbGpPWpGaD
Nelarabine—Abdominal pain—Irinotecan—pancreatic cancer	3.92e-05	0.000692	CcSEcCtD
Nelarabine—Body temperature increased—Irinotecan—pancreatic cancer	3.92e-05	0.000692	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	3.92e-05	0.000692	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PTEN—pancreatic cancer	3.91e-05	0.00193	CbGpPWpGaD
Nelarabine—Feeling abnormal—Fluorouracil—pancreatic cancer	3.91e-05	0.000691	CcSEcCtD
Nelarabine—Anaemia—Docetaxel—pancreatic cancer	3.88e-05	0.000685	CcSEcCtD
Nelarabine—Muscular weakness—Doxorubicin—pancreatic cancer	3.84e-05	0.000678	CcSEcCtD
Nelarabine—Vomiting—Sunitinib—pancreatic cancer	3.82e-05	0.000676	CcSEcCtD
Nelarabine—DGUOK—Metabolism—APOE—pancreatic cancer	3.82e-05	0.00188	CbGpPWpGaD
Nelarabine—Body temperature increased—Gemcitabine—pancreatic cancer	3.82e-05	0.000674	CcSEcCtD
Nelarabine—Neutropenia—Epirubicin—pancreatic cancer	3.8e-05	0.000671	CcSEcCtD
Nelarabine—Abdominal distension—Doxorubicin—pancreatic cancer	3.78e-05	0.000669	CcSEcCtD
Nelarabine—Headache—Sunitinib—pancreatic cancer	3.77e-05	0.000666	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	3.76e-05	0.00185	CbGpPWpGaD
Nelarabine—Leukopenia—Docetaxel—pancreatic cancer	3.76e-05	0.000664	CcSEcCtD
Nelarabine—Body temperature increased—Fluorouracil—pancreatic cancer	3.75e-05	0.000663	CcSEcCtD
Nelarabine—Loss of consciousness—Docetaxel—pancreatic cancer	3.69e-05	0.000652	CcSEcCtD
Nelarabine—Hyperglycaemia—Epirubicin—pancreatic cancer	3.66e-05	0.000648	CcSEcCtD
Nelarabine—Cough—Docetaxel—pancreatic cancer	3.66e-05	0.000647	CcSEcCtD
Nelarabine—DCK—Metabolism—ARG2—pancreatic cancer	3.64e-05	0.00179	CbGpPWpGaD
Nelarabine—Pneumonia—Epirubicin—pancreatic cancer	3.64e-05	0.000644	CcSEcCtD
Nelarabine—Convulsion—Docetaxel—pancreatic cancer	3.64e-05	0.000643	CcSEcCtD
Nelarabine—Infestation NOS—Epirubicin—pancreatic cancer	3.62e-05	0.00064	CcSEcCtD
Nelarabine—Infestation—Epirubicin—pancreatic cancer	3.62e-05	0.00064	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—MYC—pancreatic cancer	3.58e-05	0.00176	CbGpPWpGaD
Nelarabine—Arthralgia—Docetaxel—pancreatic cancer	3.57e-05	0.000631	CcSEcCtD
Nelarabine—Chest pain—Docetaxel—pancreatic cancer	3.57e-05	0.000631	CcSEcCtD
Nelarabine—Myalgia—Docetaxel—pancreatic cancer	3.57e-05	0.000631	CcSEcCtD
Nelarabine—Nausea—Sunitinib—pancreatic cancer	3.57e-05	0.000631	CcSEcCtD
Nelarabine—Asthenia—Irinotecan—pancreatic cancer	3.56e-05	0.000628	CcSEcCtD
Nelarabine—Neuropathy peripheral—Epirubicin—pancreatic cancer	3.55e-05	0.000627	CcSEcCtD
Nelarabine—Stomatitis—Epirubicin—pancreatic cancer	3.53e-05	0.000624	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	3.52e-05	0.00173	CbGpPWpGaD
Nelarabine—Neutropenia—Doxorubicin—pancreatic cancer	3.52e-05	0.000621	CcSEcCtD
Nelarabine—Asthenia—Gemcitabine—pancreatic cancer	3.46e-05	0.000612	CcSEcCtD
Nelarabine—Confusional state—Docetaxel—pancreatic cancer	3.45e-05	0.00061	CcSEcCtD
Nelarabine—ADA—Metabolism—TYMP—pancreatic cancer	3.45e-05	0.0017	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CG—pancreatic cancer	3.45e-05	0.0017	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Epirubicin—pancreatic cancer	3.43e-05	0.000605	CcSEcCtD
Nelarabine—Oedema—Docetaxel—pancreatic cancer	3.43e-05	0.000605	CcSEcCtD
Nelarabine—Epistaxis—Epirubicin—pancreatic cancer	3.42e-05	0.000604	CcSEcCtD
Nelarabine—Infection—Docetaxel—pancreatic cancer	3.4e-05	0.000601	CcSEcCtD
Nelarabine—Sinusitis—Epirubicin—pancreatic cancer	3.4e-05	0.000601	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—pancreatic cancer	3.39e-05	0.000599	CcSEcCtD
Nelarabine—Diarrhoea—Irinotecan—pancreatic cancer	3.39e-05	0.000599	CcSEcCtD
Nelarabine—Pneumonia—Doxorubicin—pancreatic cancer	3.37e-05	0.000596	CcSEcCtD
Nelarabine—Nervous system disorder—Docetaxel—pancreatic cancer	3.36e-05	0.000594	CcSEcCtD
Nelarabine—Thrombocytopenia—Docetaxel—pancreatic cancer	3.35e-05	0.000593	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—pancreatic cancer	3.35e-05	0.000592	CcSEcCtD
Nelarabine—Infestation NOS—Doxorubicin—pancreatic cancer	3.35e-05	0.000592	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PPARG—pancreatic cancer	3.33e-05	0.00164	CbGpPWpGaD
Nelarabine—Diarrhoea—Gemcitabine—pancreatic cancer	3.3e-05	0.000584	CcSEcCtD
Nelarabine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	3.29e-05	0.000581	CcSEcCtD
Nelarabine—Dizziness—Irinotecan—pancreatic cancer	3.28e-05	0.000579	CcSEcCtD
Nelarabine—Stomatitis—Doxorubicin—pancreatic cancer	3.27e-05	0.000577	CcSEcCtD
Nelarabine—Anorexia—Docetaxel—pancreatic cancer	3.26e-05	0.000577	CcSEcCtD
Nelarabine—POLA1—S Phase—MYC—pancreatic cancer	3.25e-05	0.0016	CbGpPWpGaD
Nelarabine—Diarrhoea—Fluorouracil—pancreatic cancer	3.25e-05	0.000574	CcSEcCtD
Nelarabine—Hypoaesthesia—Epirubicin—pancreatic cancer	3.24e-05	0.000572	CcSEcCtD
Nelarabine—Urinary tract disorder—Epirubicin—pancreatic cancer	3.21e-05	0.000568	CcSEcCtD
Nelarabine—Oedema peripheral—Epirubicin—pancreatic cancer	3.2e-05	0.000566	CcSEcCtD
Nelarabine—Hypotension—Docetaxel—pancreatic cancer	3.2e-05	0.000566	CcSEcCtD
Nelarabine—Connective tissue disorder—Epirubicin—pancreatic cancer	3.2e-05	0.000565	CcSEcCtD
Nelarabine—Urethral disorder—Epirubicin—pancreatic cancer	3.19e-05	0.000563	CcSEcCtD
Nelarabine—DCK—Metabolism—TYMP—pancreatic cancer	3.19e-05	0.00157	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	3.17e-05	0.00056	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—pancreatic cancer	3.16e-05	0.000559	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	3.16e-05	0.00155	CbGpPWpGaD
Nelarabine—Vomiting—Irinotecan—pancreatic cancer	3.15e-05	0.000557	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—pancreatic cancer	3.14e-05	0.000556	CcSEcCtD
Nelarabine—Dizziness—Fluorouracil—pancreatic cancer	3.14e-05	0.000555	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	3.12e-05	0.000551	CcSEcCtD
Nelarabine—Headache—Irinotecan—pancreatic cancer	3.1e-05	0.000549	CcSEcCtD
Nelarabine—Insomnia—Docetaxel—pancreatic cancer	3.1e-05	0.000547	CcSEcCtD
Nelarabine—Paraesthesia—Docetaxel—pancreatic cancer	3.08e-05	0.000544	CcSEcCtD
Nelarabine—Vomiting—Gemcitabine—pancreatic cancer	3.07e-05	0.000542	CcSEcCtD
Nelarabine—Dyspnoea—Docetaxel—pancreatic cancer	3.05e-05	0.00054	CcSEcCtD
Nelarabine—Somnolence—Docetaxel—pancreatic cancer	3.05e-05	0.000538	CcSEcCtD
Nelarabine—Eye disorder—Epirubicin—pancreatic cancer	3.04e-05	0.000537	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CD—pancreatic cancer	3.03e-05	0.00149	CbGpPWpGaD
Nelarabine—Headache—Gemcitabine—pancreatic cancer	3.02e-05	0.000534	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—pancreatic cancer	3.02e-05	0.00149	CbGpPWpGaD
Nelarabine—Cardiac disorder—Epirubicin—pancreatic cancer	3.02e-05	0.000533	CcSEcCtD
Nelarabine—Vomiting—Fluorouracil—pancreatic cancer	3.02e-05	0.000533	CcSEcCtD
Nelarabine—Hypoaesthesia—Doxorubicin—pancreatic cancer	2.99e-05	0.000529	CcSEcCtD
Nelarabine—Decreased appetite—Docetaxel—pancreatic cancer	2.98e-05	0.000526	CcSEcCtD
Nelarabine—Headache—Fluorouracil—pancreatic cancer	2.97e-05	0.000525	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.97e-05	0.000525	CcSEcCtD
Nelarabine—Oedema peripheral—Doxorubicin—pancreatic cancer	2.96e-05	0.000524	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.96e-05	0.000523	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.96e-05	0.000523	CcSEcCtD
Nelarabine—Fatigue—Docetaxel—pancreatic cancer	2.95e-05	0.000522	CcSEcCtD
Nelarabine—Angiopathy—Epirubicin—pancreatic cancer	2.95e-05	0.000521	CcSEcCtD
Nelarabine—Urethral disorder—Doxorubicin—pancreatic cancer	2.95e-05	0.000521	CcSEcCtD
Nelarabine—Nausea—Irinotecan—pancreatic cancer	2.94e-05	0.00052	CcSEcCtD
Nelarabine—Mediastinal disorder—Epirubicin—pancreatic cancer	2.93e-05	0.000518	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.93e-05	0.00144	CbGpPWpGaD
Nelarabine—Constipation—Docetaxel—pancreatic cancer	2.93e-05	0.000518	CcSEcCtD
Nelarabine—Pain—Docetaxel—pancreatic cancer	2.93e-05	0.000518	CcSEcCtD
Nelarabine—Chills—Epirubicin—pancreatic cancer	2.92e-05	0.000516	CcSEcCtD
Nelarabine—Nausea—Gemcitabine—pancreatic cancer	2.87e-05	0.000507	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	2.85e-05	0.0014	CbGpPWpGaD
Nelarabine—Mental disorder—Epirubicin—pancreatic cancer	2.85e-05	0.000503	CcSEcCtD
Nelarabine—Malnutrition—Epirubicin—pancreatic cancer	2.83e-05	0.0005	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	2.82e-05	0.00139	CbGpPWpGaD
Nelarabine—Feeling abnormal—Docetaxel—pancreatic cancer	2.82e-05	0.000499	CcSEcCtD
Nelarabine—Nausea—Fluorouracil—pancreatic cancer	2.82e-05	0.000498	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—pancreatic cancer	2.81e-05	0.000497	CcSEcCtD
Nelarabine—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.8e-05	0.000495	CcSEcCtD
Nelarabine—Cardiac disorder—Doxorubicin—pancreatic cancer	2.79e-05	0.000493	CcSEcCtD
Nelarabine—ADA—Metabolism—GLP1R—pancreatic cancer	2.78e-05	0.00137	CbGpPWpGaD
Nelarabine—Dysgeusia—Epirubicin—pancreatic cancer	2.77e-05	0.00049	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	2.75e-05	0.00136	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—TYMS—pancreatic cancer	2.74e-05	0.00135	CbGpPWpGaD
Nelarabine—Back pain—Epirubicin—pancreatic cancer	2.74e-05	0.000484	CcSEcCtD
Nelarabine—ADA—Metabolism—DPYD—pancreatic cancer	2.74e-05	0.00135	CbGpPWpGaD
Nelarabine—Angiopathy—Doxorubicin—pancreatic cancer	2.73e-05	0.000482	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.71e-05	0.000479	CcSEcCtD
Nelarabine—Abdominal pain—Docetaxel—pancreatic cancer	2.71e-05	0.000478	CcSEcCtD
Nelarabine—Body temperature increased—Docetaxel—pancreatic cancer	2.71e-05	0.000478	CcSEcCtD
Nelarabine—Chills—Doxorubicin—pancreatic cancer	2.7e-05	0.000477	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—TP53—pancreatic cancer	2.67e-05	0.00131	CbGpPWpGaD
Nelarabine—Vision blurred—Epirubicin—pancreatic cancer	2.67e-05	0.000471	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CB—pancreatic cancer	2.64e-05	0.0013	CbGpPWpGaD
Nelarabine—Mental disorder—Doxorubicin—pancreatic cancer	2.64e-05	0.000466	CcSEcCtD
Nelarabine—Malnutrition—Doxorubicin—pancreatic cancer	2.62e-05	0.000463	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTGS2—pancreatic cancer	2.62e-05	0.00129	CbGpPWpGaD
Nelarabine—Anaemia—Epirubicin—pancreatic cancer	2.62e-05	0.000462	CcSEcCtD
Nelarabine—ADA—Metabolism—SLC2A2—pancreatic cancer	2.6e-05	0.00128	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—BRCA2—pancreatic cancer	2.58e-05	0.00127	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GLP1R—pancreatic cancer	2.57e-05	0.00126	CbGpPWpGaD
Nelarabine—Dysgeusia—Doxorubicin—pancreatic cancer	2.56e-05	0.000453	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	2.55e-05	0.00126	CbGpPWpGaD
Nelarabine—Leukopenia—Epirubicin—pancreatic cancer	2.53e-05	0.000448	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—pancreatic cancer	2.53e-05	0.000448	CcSEcCtD
Nelarabine—DCK—Metabolism—DPYD—pancreatic cancer	2.53e-05	0.00124	CbGpPWpGaD
Nelarabine—Loss of consciousness—Epirubicin—pancreatic cancer	2.49e-05	0.00044	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	2.49e-05	0.00122	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—RB1—pancreatic cancer	2.49e-05	0.00122	CbGpPWpGaD
Nelarabine—Cough—Epirubicin—pancreatic cancer	2.47e-05	0.000437	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—pancreatic cancer	2.47e-05	0.000436	CcSEcCtD
Nelarabine—Asthenia—Docetaxel—pancreatic cancer	2.46e-05	0.000434	CcSEcCtD
Nelarabine—Convulsion—Epirubicin—pancreatic cancer	2.45e-05	0.000433	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TYMS—pancreatic cancer	2.45e-05	0.00121	CbGpPWpGaD
Nelarabine—Anaemia—Doxorubicin—pancreatic cancer	2.42e-05	0.000428	CcSEcCtD
Nelarabine—Myalgia—Epirubicin—pancreatic cancer	2.41e-05	0.000426	CcSEcCtD
Nelarabine—Chest pain—Epirubicin—pancreatic cancer	2.41e-05	0.000426	CcSEcCtD
Nelarabine—Arthralgia—Epirubicin—pancreatic cancer	2.41e-05	0.000426	CcSEcCtD
Nelarabine—DCK—Metabolism—SLC2A2—pancreatic cancer	2.4e-05	0.00118	CbGpPWpGaD
Nelarabine—Leukopenia—Doxorubicin—pancreatic cancer	2.34e-05	0.000414	CcSEcCtD
Nelarabine—Diarrhoea—Docetaxel—pancreatic cancer	2.34e-05	0.000414	CcSEcCtD
Nelarabine—Confusional state—Epirubicin—pancreatic cancer	2.33e-05	0.000412	CcSEcCtD
Nelarabine—Oedema—Epirubicin—pancreatic cancer	2.31e-05	0.000408	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—pancreatic cancer	2.3e-05	0.000407	CcSEcCtD
Nelarabine—Infection—Epirubicin—pancreatic cancer	2.3e-05	0.000406	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	2.29e-05	0.00113	CbGpPWpGaD
Nelarabine—Cough—Doxorubicin—pancreatic cancer	2.29e-05	0.000404	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTEN—pancreatic cancer	2.28e-05	0.00112	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	2.28e-05	0.00112	CbGpPWpGaD
Nelarabine—Convulsion—Doxorubicin—pancreatic cancer	2.27e-05	0.000401	CcSEcCtD
Nelarabine—Nervous system disorder—Epirubicin—pancreatic cancer	2.27e-05	0.0004	CcSEcCtD
Nelarabine—Dizziness—Docetaxel—pancreatic cancer	2.27e-05	0.0004	CcSEcCtD
Nelarabine—Thrombocytopenia—Epirubicin—pancreatic cancer	2.26e-05	0.0004	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	2.24e-05	0.0011	CbGpPWpGaD
Nelarabine—Chest pain—Doxorubicin—pancreatic cancer	2.23e-05	0.000394	CcSEcCtD
Nelarabine—Arthralgia—Doxorubicin—pancreatic cancer	2.23e-05	0.000394	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—pancreatic cancer	2.23e-05	0.000394	CcSEcCtD
Nelarabine—Anorexia—Epirubicin—pancreatic cancer	2.2e-05	0.000389	CcSEcCtD
Nelarabine—Vomiting—Docetaxel—pancreatic cancer	2.18e-05	0.000385	CcSEcCtD
Nelarabine—Hypotension—Epirubicin—pancreatic cancer	2.16e-05	0.000381	CcSEcCtD
Nelarabine—Confusional state—Doxorubicin—pancreatic cancer	2.16e-05	0.000381	CcSEcCtD
Nelarabine—Headache—Docetaxel—pancreatic cancer	2.15e-05	0.000379	CcSEcCtD
Nelarabine—Oedema—Doxorubicin—pancreatic cancer	2.14e-05	0.000378	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TERT—pancreatic cancer	2.14e-05	0.00105	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	2.13e-05	0.00105	CbGpPWpGaD
Nelarabine—Infection—Doxorubicin—pancreatic cancer	2.12e-05	0.000375	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	2.11e-05	0.00104	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.1e-05	0.000372	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—pancreatic cancer	2.1e-05	0.00037	CcSEcCtD
Nelarabine—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.09e-05	0.00037	CcSEcCtD
Nelarabine—Insomnia—Epirubicin—pancreatic cancer	2.09e-05	0.000369	CcSEcCtD
Nelarabine—Paraesthesia—Epirubicin—pancreatic cancer	2.07e-05	0.000367	CcSEcCtD
Nelarabine—Dyspnoea—Epirubicin—pancreatic cancer	2.06e-05	0.000364	CcSEcCtD
Nelarabine—Somnolence—Epirubicin—pancreatic cancer	2.05e-05	0.000363	CcSEcCtD
Nelarabine—Anorexia—Doxorubicin—pancreatic cancer	2.04e-05	0.00036	CcSEcCtD
Nelarabine—Nausea—Docetaxel—pancreatic cancer	2.03e-05	0.00036	CcSEcCtD
Nelarabine—ADA—Metabolism—CD44—pancreatic cancer	2.01e-05	0.00099	CbGpPWpGaD
Nelarabine—Decreased appetite—Epirubicin—pancreatic cancer	2.01e-05	0.000355	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—pancreatic cancer	2e-05	0.000353	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.99e-05	0.000352	CcSEcCtD
Nelarabine—Fatigue—Epirubicin—pancreatic cancer	1.99e-05	0.000352	CcSEcCtD
Nelarabine—Constipation—Epirubicin—pancreatic cancer	1.98e-05	0.000349	CcSEcCtD
Nelarabine—Pain—Epirubicin—pancreatic cancer	1.98e-05	0.000349	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.95e-05	0.000344	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.94e-05	0.000956	CbGpPWpGaD
Nelarabine—Insomnia—Doxorubicin—pancreatic cancer	1.93e-05	0.000342	CcSEcCtD
Nelarabine—ADA—Metabolism—GCG—pancreatic cancer	1.93e-05	0.000949	CbGpPWpGaD
Nelarabine—Paraesthesia—Doxorubicin—pancreatic cancer	1.92e-05	0.000339	CcSEcCtD
Nelarabine—Dyspnoea—Doxorubicin—pancreatic cancer	1.91e-05	0.000337	CcSEcCtD
Nelarabine—Feeling abnormal—Epirubicin—pancreatic cancer	1.9e-05	0.000336	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—pancreatic cancer	1.9e-05	0.000336	CcSEcCtD
Nelarabine—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.89e-05	0.000334	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.88e-05	0.000925	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—RB1—pancreatic cancer	1.86e-05	0.000915	CbGpPWpGaD
Nelarabine—Decreased appetite—Doxorubicin—pancreatic cancer	1.86e-05	0.000328	CcSEcCtD
Nelarabine—DCK—Metabolism—CD44—pancreatic cancer	1.86e-05	0.000914	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.85e-05	0.000326	CcSEcCtD
Nelarabine—Fatigue—Doxorubicin—pancreatic cancer	1.84e-05	0.000326	CcSEcCtD
Nelarabine—Pain—Doxorubicin—pancreatic cancer	1.83e-05	0.000323	CcSEcCtD
Nelarabine—Constipation—Doxorubicin—pancreatic cancer	1.83e-05	0.000323	CcSEcCtD
Nelarabine—Abdominal pain—Epirubicin—pancreatic cancer	1.83e-05	0.000323	CcSEcCtD
Nelarabine—Body temperature increased—Epirubicin—pancreatic cancer	1.83e-05	0.000323	CcSEcCtD
Nelarabine—ADA—Metabolism—STK11—pancreatic cancer	1.81e-05	0.000892	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GCG—pancreatic cancer	1.78e-05	0.000876	CbGpPWpGaD
Nelarabine—Feeling abnormal—Doxorubicin—pancreatic cancer	1.76e-05	0.000311	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.75e-05	0.000309	CcSEcCtD
Nelarabine—Abdominal pain—Doxorubicin—pancreatic cancer	1.69e-05	0.000299	CcSEcCtD
Nelarabine—Body temperature increased—Doxorubicin—pancreatic cancer	1.69e-05	0.000299	CcSEcCtD
Nelarabine—DCK—Metabolism—STK11—pancreatic cancer	1.67e-05	0.000824	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RB1—pancreatic cancer	1.66e-05	0.000818	CbGpPWpGaD
Nelarabine—Asthenia—Epirubicin—pancreatic cancer	1.66e-05	0.000293	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	1.63e-05	0.000804	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CA—pancreatic cancer	1.61e-05	0.000793	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.59e-05	0.000781	CbGpPWpGaD
Nelarabine—Diarrhoea—Epirubicin—pancreatic cancer	1.58e-05	0.000279	CcSEcCtD
Nelarabine—ADA—Metabolism—TYMS—pancreatic cancer	1.56e-05	0.000768	CbGpPWpGaD
Nelarabine—Asthenia—Doxorubicin—pancreatic cancer	1.53e-05	0.000271	CcSEcCtD
Nelarabine—Dizziness—Epirubicin—pancreatic cancer	1.53e-05	0.00027	CcSEcCtD
Nelarabine—Vomiting—Epirubicin—pancreatic cancer	1.47e-05	0.00026	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—pancreatic cancer	1.46e-05	0.000258	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CDKN2A—pancreatic cancer	1.46e-05	0.000719	CbGpPWpGaD
Nelarabine—Headache—Epirubicin—pancreatic cancer	1.45e-05	0.000256	CcSEcCtD
Nelarabine—DCK—Metabolism—TYMS—pancreatic cancer	1.44e-05	0.000708	CbGpPWpGaD
Nelarabine—Dizziness—Doxorubicin—pancreatic cancer	1.41e-05	0.00025	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.38e-05	0.00068	CbGpPWpGaD
Nelarabine—Nausea—Epirubicin—pancreatic cancer	1.37e-05	0.000243	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—pancreatic cancer	1.36e-05	0.00024	CcSEcCtD
Nelarabine—Headache—Doxorubicin—pancreatic cancer	1.34e-05	0.000237	CcSEcCtD
Nelarabine—DGUOK—Metabolism—AKT1—pancreatic cancer	1.32e-05	0.000648	CbGpPWpGaD
Nelarabine—Nausea—Doxorubicin—pancreatic cancer	1.27e-05	0.000224	CcSEcCtD
Nelarabine—ADA—Metabolism—APOE—pancreatic cancer	1.27e-05	0.000624	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—pancreatic cancer	1.23e-05	0.000608	CbGpPWpGaD
Nelarabine—DCK—Metabolism—APOE—pancreatic cancer	1.17e-05	0.000576	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CG—pancreatic cancer	1.14e-05	0.000563	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.11e-05	0.000545	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARG—pancreatic cancer	1.1e-05	0.000544	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CG—pancreatic cancer	1.06e-05	0.00052	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARG—pancreatic cancer	1.02e-05	0.000502	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CD—pancreatic cancer	1.01e-05	0.000495	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—pancreatic cancer	9.9e-06	0.000487	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CD—pancreatic cancer	9.29e-06	0.000457	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CB—pancreatic cancer	8.77e-06	0.000432	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—pancreatic cancer	8.69e-06	0.000428	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—pancreatic cancer	8.13e-06	0.0004	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CB—pancreatic cancer	8.09e-06	0.000398	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—pancreatic cancer	8.02e-06	0.000395	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTEN—pancreatic cancer	7.58e-06	0.000373	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTEN—pancreatic cancer	6.99e-06	0.000344	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CA—pancreatic cancer	5.35e-06	0.000263	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CA—pancreatic cancer	4.93e-06	0.000243	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AKT1—pancreatic cancer	4.37e-06	0.000215	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AKT1—pancreatic cancer	4.03e-06	0.000198	CbGpPWpGaD
